Renal complications of cancer therapies
Schanz M, Schricker S, Pfister F, Alscher MD, Kimmel M (2018)
Publication Type: Journal article
Publication year: 2018
Journal
Book Volume: 54
Pages Range: 561-575
Journal Issue: 9
DOI: 10.1358/dot.2018.54.9.2874064
Abstract
Cancer patients often exhibit preexisting renal impairment and are simultaneously at risk for developing further kidney injury due to direct or indirect complications of oncological therapies. The nature of kidney injury is highly dependent on the therapy regimen used, and the spectrum of possible kidney stressors has widened as a result of the development of new therapeutic modalities such as molecular therapy or immunotherapy. Indirect renal complications are often due to volume depletion or other therapy-related side effects. Direct toxicity from "classic" chemotherapy treatments such as cisplatin usually leads to acute tubular necrosis, whereas treatment with protein kinase inhibitors is more likely to cause disorders such as thrombotic microangiopathy. Immunotherapy often affects kidneys through the development of acute interstitial nephritis. Because of the high risk of nephrological complications in oncological patients, close monitoring of renal function and the early involvement of a nephrologist are strongly recommended.
Involved external institutions
Germany (DE)How to cite
APA:
Schanz, M., Schricker, S., Pfister, F., Alscher, M.D., & Kimmel, M. (2018). Renal complications of cancer therapies. Drugs of Today, 54(9), 561-575. https://dx.doi.org/10.1358/dot.2018.54.9.2874064
MLA:
Schanz, M., et al. "Renal complications of cancer therapies." Drugs of Today 54.9 (2018): 561-575.
BibTeX: Download